All In Biotech

Drug Trial Radar · NCT04785768

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Intravenous (IV) Patient Controlled Analgesia (PCA) With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Hydromorphone Titration: a Multi-center, Phase Ⅲ ,Randomized Trial

Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,372

Actual

Start

Jul 1, 2021

Primary completion

May 1, 2024

Study completion Jul 1, 2024

Sponsor

Lead sponsor
Fujian Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Based on the previous HMORCT09-2, the results show that IV PCA for analgesia maintenance improvements control of severe cancer pain after successful titration. Therefore, a study is planned to further explore the difference of efficacy and safety between PCA with continuous + bolus dose versus bolus-only.

Conditions

  • Cancer Pain

Interventions

  • Hydromorphone Hydrochloride InjectionDrug

    Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.

  • Hydromorphone Hydrochloride InjectionDrug

    Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.

  • Morphine Sulfate Sustained-release TabletsDrug

    Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours. Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2)the total equianalgesic of the previous 24 hours/2 for day 2 ; 3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day;4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3DNRS (3-day average Numeric Rating Scale)Time frame: up to 4 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China, Fujian

    Fuzhou, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.